Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects necessitating effective, fast-acting, and better tolerated alternatives. The purpose of this review is to describe the safety and efficacy of dextromethorphan-bupropion (Auvelity), a Food and Drug Administration approved treatment for major depressive disorder in adults. Dextromethorphan modulates glutamate signaling through uncompetitive antagonism of N-methyl-D-aspartate receptors and sigma-1 agonism, while bupropion increases the bioavailability of dextromethorphan by CYP2D6 inhibition. In a phase 3 trial with dextromethorphan-bupropion 45−105 mg for patients with major depressive disorder saw significant reductions in their Montgomery–Åsberg Depression Rating Scale total scores compared to placebo. A phase 2 trial comparing dextromethorphan-bupropion 45−105 mg to bupropion monotherapy led to significant reduction in Montgomery-Åsberg Depression Rating Scale score. Changes in Montgomery–Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials. Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies. The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate. Two long-term, open-label studies with dextromethorphan-bupropion saw large reductions in Montgomery–Åsberg Depression Rating Scale scores that were maintained through 12 and 15 months of treatment. In both long-term studies, remission rates approached 70%, while response rates were greater than 80%. These data suggest that dextromethorphan-bupropion is an effective, fast-acting, and well tolerated option for depression treatment and produced remission in a large percentage of patients.
Abstract
Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects necessitating effective, fast-acting, and better tolerated alternatives. The purpose of this review is to describe the safety and efficacy of dextromethorphan-bupropion (Auvelity), a Food and Drug Administration approved treatment for major depressive disorder in adults. Dextromethorphan modulates glutamate signaling through uncompetitive antagonism of N-methyl-D-aspartate receptors and sigma-1 agonism, while bupropion increases the bioavailability of dextromethorphan by CYP2D6 inhibition. In a phase 3 trial with dextromethorphan-bupropion 45−105 mg for patients with major depressive disorder saw significant reductions in their Montgomery–Åsberg Depression Rating Scale total scores compared to placebo. A phase 2 trial comparing dextromethorphan-bupropion 45−105 mg to bupropion monotherapy led to significant reduction in Montgomery-Åsberg Depression Rating Scale score. Changes in Montgomery–Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials. Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies. The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate. Two long-term, open-label studies with dextromethorphan-bupropion saw large reductions in Montgomery–Åsberg Depression Rating Scale scores that were maintained through 12 and 15 months of treatment. In both long-term studies, remission rates approached 70%, while response rates were greater than 80%. These data suggest that dextromethorphan-bupropion is an effective, fast-acting, and well tolerated option for depression treatment and produced remission in a large percentage of patients.
참고문헌 (27)
- "Depression" (2021)[URL]
- Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
- Cheng Q, "Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression", Int J Neuropsychopharmacol, 23, pp.76~87 (2020)
- "Practice Guideline for the treatment of patients with major depressive disorder, third edition" (2010)[URL]
- "Depression in adults: Treatment and management" (2022)[URL]
- Cipriani A, "Comparative efficacy and acceptability of 21antidepressant drugs for the acute treatment of adults with major depressive disorder : A systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
- Anderson HD, "Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression : A retrospective US claims study", Clin Ther, 34, pp.113~123 (2012)
- Henssler J, "Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression : A systematic review and meta-analysis", JAMA Psychiatry, 79, pp.300~312 (2022)
- Blier P, "Combination of antidepressant medications from treatment initiation for major depressive disorder : A double-blind randomized study", Am J Psychiatry, 167, pp.281~288 (2010)
- "Aripiprazole" (2013)[URL]
- "Brexpiprazole" (2021)[URL]
- "U.S. FDA approves VRAYLAR® (cariprazine) as an adjunctive treatment for major depressive disorder" (2022)[URL]
- "Olanzapine-Fluoxetine" (2003)[URL]
- "Quetiapine Extended-Release" (2009)[URL]
- "Esketamine" (2019)[URL]
- "Dextromethorphan-bupropion" (2022)[URL]
- Tabuteau H, "Effect of AXS-05(Dextromethorphan-Bupropion)in major depressive disorder : A randomized double-blind controlled trial", Am J Psychiatry, 179, pp.490~499 (2022)
- Iosifescu DV, "Efficacy and safety of AXS-05(Dextromethorphan-Bupropion)in patients with major depressive disorder : A phase 3 randomized clinical trial(GEMINI)", J Clin Psychiatry, 83, pp.21~ (2022)
- Stahl SM, "Dextromethorphan", bupropion : a novel oral NMDA(N-methyl-d-aspartate)receptor antagonist with multimodal activity, 2019, pp.24, 461~466
- Kourrich S, "The sigma-1 receptor : roles in neuronal plasticity and disease", Trends Neurosci, 35, pp.762~771 (2012)
- O’Gorman C, "Sustained efficacy with long-term treatment with AXS-05: Results from the COMET phase 3 trial, a long-term, open-label study evaluating the efficacy and safety of AXS-05 for the treatment of MDD", American Society of Clinical Psychopharmacology Annual Meeting (2021)
- Jones A, "Improvements in cognitive and physical functioning outcomes in depressed patients treated with AXS-05 (dextromethorphanbupropion):Results from the EVOLVE open-label, long-term study", American College of Neuropsychopharmacology Annual Meeting (2022)
- "Spravato REMS" (2020)[URL]
- "Brexanolone" (2019)[URL]
- Romanelli F, "Dextromethorphan abuse: Clinical effects and management", J Am Pharm Assoc(2003), 49, pp.e20~e25 (2009)
- Nicholson KL, "Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys", Psychopharmacology(Berl), 146, pp.49~59 (1999)
- "Axsome Therapeutics" (2020)[URL]